Association of Nirmatrelvir/Ritonavir treatment and COVID-19 neutralizing antibody titers in a longitudinal healthcare worker cohort
Decker, S.; Xiao, S.; Dillen, C.; Schumacher, C.; Milstone, A. M.; Frieman, M.; Debes, A. K.
Show abstract
Nirmatrelvir/Ritonavir (NMV/r) is used for the treatment of COVID-19 infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the SARS-CoV-2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-CoV-2 virus dynamics in recently infected people – data from a household transmission study 95%
- Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine 94%
- SARS-CoV-2 seroassay optimization and performance in a population with high background reactivity in Mali 94%
Similar papers in this journal
- Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Infectious Virus Loads Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals 95%
- Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV 95%
- High household transmission of SARS-CoV-2 in the United States: living density, viral load, and disproportionate impact on communities of color 95%
Similar papers in this journal
- SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection 94%
- Immunization by exposure to live virus (SIVmne/HIV-2287) during antiretroviral drug prophylaxis reduces risk of subsequent viral challenge 93%
- Development of a Novel Medium Throughput Flow-Cytometry Based Micro-Neutralisation Test for SARS-CoV-2 with Applications in Clinical Vaccine Trials and Antibody Screening 93%
Similar papers in this journal
- SARS-CoV-2 subgenomic RNA kinetics in longitudinal clinical samples 94%
- A multidimensional cross-sectional analysis of COVID-19 seroprevalence among a police officer cohort: The PoliCOV-19 study 94%
- Vaccine-induced antibody level predicts the clinical course of breakthrough infection of COVID-19 caused by delta and omicron variants: a prospective observational cohort study 93%
Similar papers in this journal
- Characteristics of anti-SARS-CoV-2 antibodies in recovered COVID-19 subjects 95%
- SARS-CoV-2 variants from long-term, persistently infected immunocompromised patients have altered syncytia formation, temperature-dependent replication, and serum neutralizing antibody escape 93%
- Scalable, Micro-Neutralization Assay for Qualitative Assessment of SARS-CoV-2 (COVID 19) Virus-Neutralizing Antibodies in Human Clinical Samples 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.